ライフサイエンスコーパス: pimonidazole

1 with surrogate hypoxic markers (for example, pimonidazole).

2 (glucose transporter protein 1 [Glut-1] and pimonidazole).

3 o using the 2-nitroimidazole hypoxia marker, pimonidazole.

4 umor area staining positive for both EF5 and pimonidazole.

5 Prior to MR imaging, rats were administered pimonidazole.

6 sitive for the binding of the hypoxic marker pimonidazole.

7 etermine the rate of reductive metabolism of pimonidazole.

8 nt CT prior to intravenous administration of pimonidazole (0.5 g/m(2)), a marker of hypoxia, 24 hours

9 re they were killed, rats were injected with pimonidazole (120 mg/kg intravenously), and livers were

10 used with oxygen-saturated buffer containing pimonidazole (400 microM) in the presence and absence of

11 s and by immunohistochemical comparison with pimonidazole, a well-established hypoxia marker drug.

12 YC-1 + GI reduced HIF-1alpha expression and pimonidazole accumulation in tumours.

13 Significant correlations were found between pimonidazole adduct formation and both baseline tumor R2

14 nd nonhuman primate showed discrete areas of pimonidazole adduct formation surrounding necrotic and c

15 In retinal cells and mouse retinal tissue, pimonidazole-adduct immunostaining confirmed the hypoxia

16 actor-beta, tumor necrosis factor-alpha, and pimonidazole adducts (as a hypoxia marker) were followed

17 However, KCN had no effect on total pimonidazole adducts detected by ELISA, although both cy

18 Immunohistochemical detection of pimonidazole adducts on adjacent tissue sections confirm

19 Protein-bound pimonidazole adducts were identified on formalin-fixed,

20 In contrast, reduced pimonidazole adducts, detected immunochemically, accumul

21 atory chain with KCN decreased protein-bound pimonidazole adducts.

22 d virulent MTB-strain H37Rv was localized to pimonidazole (an in vivo hypoxia marker) positive CD271(

23 ll showed radiotracer uptake increasing with pimonidazole and CA9 staining.

24 r uptake observed in regions with the lowest pimonidazole and CA9 staining.

25 p was observed with 2 other hypoxia markers, pimonidazole and carbonic anhydrase IX, in FSA tumors.

26 Pimonidazole and CCL-2 positive staining diminished when

27 d (18)F-FDG together with the hypoxia marker pimonidazole and cellular proliferation marker bromodeox

28 istered with the established hypoxia markers pimonidazole and EF5 in nine rats; 12-hour PET data acqu

29 ur noninvasive in vivo hypoxia PET data with pimonidazole and expression of HIF-1alpha in arthritic a

30 derived at DCE CT correlated negatively with pimonidazole and glucose transporter protein expression,

31 e was also a significant correlation between pimonidazole and sirius red staining (r = 0.76, P < .01)

32 tected by immunofluorescent visualization of pimonidazole and the hypoxia-regulated protein carbonic

33 These cells stained positively for pimonidazole and therefore generated hypoxic stress with

34 for microscopic visualization of perfusion (pimonidazole) and hypoxia (Hoechst 33342).

35 ly by histopathologic assessment of hypoxia (pimonidazole) and vascularity (CD31).

36 calized with macrophages (CD68) and hypoxia (pimonidazole), and correlated with lipid core size and p

37 2-Nitroimidazoles, such as pimonidazole, are reduced in cells with low oxygen tensi

38 Here, we investigate the use of pimonidazole as an exogenous hypoxia marker for matrix-a

39 kidneys and skeletal muscle showed enhanced pimonidazole binding and vascular endothelial growth fac

40 Quantitative image-analysis of pimonidazole binding showed that 4 weeks of ethanol admi

41 Ethanol also increased pimonidazole binding significantly at 7 days, long befor

42 Pimonidazole binding, which reflects tissue hypoxia, was

43 Hypoxia characterization (pimonidazole, CA-IX and HIF-1a) was also performed in di

44 ed with histologic markers of tumor hypoxia (pimonidazole, carbonic anydrase 9 [CA9]) and vascular pe

45 nd number of cells that stained positive for pimonidazole compared with control animals given an ente

46 FIAU and (18)F-FMISO were similar, and eGFP, pimonidazole, EF5, and CA9 colocalized in the same areas

47 ctin-TRITC (functional blood vessels), eGFP, pimonidazole, EF5, and CA9.

48 unofluorescence microscopic visualization of pimonidazole, EF5, the Hoechst 33342, CD31, and alpha-sm

49 the average intensity of tumor staining with pimonidazole (for SD: filter value, 2.5; slope = 0.003;

50 ution was compared with the distributions of pimonidazole, GLUT-1 expression, bromodeoxyuridine, and

51 ontrast-enhanced magnetic resonance imaging, pimonidazole, HIF-1alpha).

52 Additionally, we performed ex vivo pimonidazole-/HIF-1alpha immunohistochemistry and HIF-1a

53 8)F-FDG (100 MBq), (14)C-2DG (0.37 MBq), and pimonidazole hydrochloride (60 mg/kg).

54 Pimonidazole hydrochloride (Hypoxyprobe) is an imaging a

55 (ZO-1) and anti-occludin], and hypoxia [anti-pimonidazole hydrochloride (Hypoxyprobe-1)].

56 ociated angiogenic factors were evaluated by pimonidazole hydrochloride staining and quantitative rev

57 Pimonidazole hydrochloride-based assays were used to ide

58 minantly in macrophage-rich hypoxic regions (pimonidazole(+)/hypoxia-inducible factor-1alpha(+)/RAM-1

59 t localization of the hypoxia-sensitive drug pimonidazole (hypoxyprobe, HP).

60 Pimonidazole immunohistochemistry at 8 wk colocalized to

61 ography in live infected animals, postmortem pimonidazole immunohistochemistry, and bacterial gene ex

62 Using the hypoxia marker pimonidazole in vivo, we found that MCs were largely loc

63 Pimonidazole-induced increases in oxygen uptake over bas

64 exogenous and endogenous markers of hypoxia (pimonidazole infused intravenously 24 hours before surge

65 ach is also applicable to other tissues from pimonidazole-injected animals or humans.

66 for tumor burden, percentage of hypoxia, and pimonidazole intensity (P < 0.001).

67 The percentage of hypoxia and pimonidazole intensity decreased after treatment with 2-

68 Following infusion of pimonidazole into animals with established infections, l

69 As pimonidazole is a widely used immunohistochemical marker

70 accumulation of the reduced bound product of pimonidazole is oxygen dependent in liver.

71 In hypoxic cells, pimonidazole is reduced and forms reactive products that

72 sment of hypoxic macrophages (hypoxia marker pimonidazole, macrophage marker RAM-11, and hypoxia-indu

73 After imaging, plaque hypoxia (pimonidazole), macrophages (RAM-11), neovessels (CD31),

74 s, and immunohistochemical staining detected pimonidazole metabolism in hypoxic cells.

75 We show that a reductively activated pimonidazole metabolite can be imaged by MALDI-MSI in a

76 degrees of acute anemia, as assessed by the pimonidazole method and vascular endothelial growth fact

77 ry after injection of the biochemical marker pimonidazole or by staining for caspase-3, respectively.

78 ed specifically with both CA IX antibody and pimonidazole (Pimo), and was located away from non-hypox

79 of ethanol administration nearly doubled the pimonidazole-positive area in tissue.

80 ssue samples were collected and analyzed for pimonidazole-protein adduct quantification (dot blot) an

81 AZGP distribution correlated positively with pimonidazole (r = 0.78) and EF5 (r = 0.76) distribution.

82 ct of the pyridine nucleotide redox state on pimonidazole reduction is not known.

83 fluorescence analysis of the hypoxia marker, pimonidazole, showed that collecting ducts and many deve

84 Tumor sections were subsequently stained for pimonidazole, sirius red, cytokeratin 14, and hematoxyli

85 ined levels with hypoxia levels reflected in pimonidazole-stained histologic sections.

86 gative correlations between blood volume and pimonidazole staining (r = -0.48, P = .004), and between

87 Pimonidazole staining also showed that TM elevates oxyge

88 ime in addition to Western blot analysis and pimonidazole staining for cellular hypoxia, we demonstra

89 Pimonidazole staining patterns in FSA and 9L tumors supp

90 Pimonidazole staining, a hypoxia marker, was increased b

91 th improved tumor oxygenation as assessed by pimonidazole staining, decreased HIF-1alpha protein leve

92 Pimonidazole staining, HIF-1A accumulation, and VEGFA re

93 with the ex vivo hypoxia assessment by using pimonidazole staining.

94 tion, and degree of hypoxia as determined by pimonidazole staining.

95 These results indicate that pimonidazole-stimulated O2 uptake, due predominantly to

96 he present study, we used the hypoxia marker pimonidazole to demonstrate the presence of hypoxia in a

97 luoropropyl)acetamide (EF5) and beta-hCG and pimonidazole, two extrinsic markers for tumor hypoxia.

98 To assess hypoxia, mice received 60 mg/kg pimonidazole via intraperitoneal injection.

99 Pimonidazole was coadministered with the first (18)F-FMI

100 oxygen uptake due to oxidative metabolism of pimonidazole was independent of treatment.

101 hypoxic tumor cell population as measured by pimonidazole was markedly reduced by carboplatin + 2-DG

102 translational side study, the hypoxia marker pimonidazole was used to assess the oxygenation status i

103 The hypoxia marker pimonidazole was used to measure tumor hypoxia, and a co

104 Subsequently, 10 mg/kg pimonidazole (which forms protein adducts in hypoxic cel

105 mpound 2 images similar levels of hypoxia to pimonidazole, while compound 4 images more extreme hypox